title: Lung infections in pediatric lung transplantation: experience in 49 cases.
abstract: OBJECTIVE
  Pulmonary infections, and particularly cytomegalovirus (CMV) infections, are a major cause of morbidity after lung transplantation. We report here our results in 49 pediatric lung transplantations.
  
  
  METHODS
  Between may 1988 and 1997, we have done 49 lung transplantations in 42 children (en bloc double lung transplantation (DLT):10, HLTx:7, sequential bilateral sequential-lung transplantation (BSLT):31, single-lung transplantation (SLT): 1). In seven, it was a retransplantation. Among these, 34 were cystic fibrosis (CF) patients, all with multiresistant organisms (Pseudomonas aeruginosa, Burkholderia cepacia, Achromobacter xylososydans, Staphylococcus aureus). All patients were treated with multiantibiotic prophylaxy adapted to the preoperative cultures. Donor-recipient CMV matching was possible in only 31 cases. CMV prophylaxy and immunosuppression protocols have evolved with time, with a current protocol of IV Gancyclovir prophylaxy for 3 months and triple drug immunosuppression without post-operative rabbit anti-thymocyte globulin (RATG) induction. There was no perioperative mortality in the primary transplantations and three early deaths in the whole group (6.1%).
  
  
  RESULTS
  Only five patients had no pulmonary infection. The patients presented 3.2 infection episodes per year, 75% localized on the lungs, 41% during the first 3 months. Among the 13 deaths in the 1st year, 10 were directly related to infection, 60% due to CMV. After the 1st year, in all patients dying of pulmonary dysfunction or obliterative bronchiolitis (OB), bacterial infections were associated. There was no serious fungal infection. Actuarial survival at 3 months, 1, 3, 5 years were 85, 65.7, 47.5 and 28.5%, respectively. There was a significant difference in 3 year survival between patients receiving CMV negative organs (40%) and CMV positive organs (17%).
  
  
  CONCLUSIONS
  In our experience, as in other's, pulmonary infection risk is important in lung transplantation. Bacterial infections were mainly an aggravating factor of secondary pulmonary dysfunction or OB, and were not the primary cause of death. CMV infections have been very severe and lead us, despite the scarcity of donors, to avoid positive donors in negative recipients, this leads to disastrous mid-term results in our experience, despite prophylaxis.
authors.affiliation: Cardiothoracic Surgery Service, La Timone Children's Hospital, Marseilles, France. dmetras@ap-hm
authors.forename: D
authors.initials: D
authors.lastname: Metras
authors.forename: L
authors.initials: L
authors.lastname: Viard
authors.forename: B
authors.initials: B
authors.lastname: Kreitmann
authors.forename: A
authors.initials: A
authors.lastname: Riberi
authors.forename: A
authors.initials: A
authors.lastname: Pannetier-Mille
authors.forename: O
authors.initials: O
authors.lastname: Garbi
authors.forename: J Y
authors.initials: JY
authors.lastname: Marti
authors.forename: P
authors.initials: P
authors.lastname: Geigle
mesh_terms: D000293:Adolescent; D019072:Antibiotic Prophylaxis; D002648:Child; D003550:Cystic Fibrosis / Q000601:surgery; D003586:Cytomegalovirus Infections / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008171:Lung Diseases / Q000209:etiology* / Q000601:surgery; D016040:Lung Transplantation / Q000009:adverse effects* / Q000379:methods; D012141:Respiratory Tract Infections / Q000209:etiology*
chemical_list: D007166:Immunosuppressive Agents